CY1124031T1 - Ετεροαρυλ υποκατεστημενες πυριδινες και μεθοδοι χρησης - Google Patents
Ετεροαρυλ υποκατεστημενες πυριδινες και μεθοδοι χρησηςInfo
- Publication number
- CY1124031T1 CY1124031T1 CY20201100646T CY201100646T CY1124031T1 CY 1124031 T1 CY1124031 T1 CY 1124031T1 CY 20201100646 T CY20201100646 T CY 20201100646T CY 201100646 T CY201100646 T CY 201100646T CY 1124031 T1 CY1124031 T1 CY 1124031T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- heteroaryl substituted
- substituted pyridines
- cystic fibrosis
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 150000003222 pyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η εφεύρεση αποκαλύπτει ενώσεις του Τύπου (Ι), όπου τα Χ1, Χ2, R1 και R2 είναι όπως ορίζεται στο παρόν. Η παρούσα εφεύρεση αφορά ενώσεις και τη χρήση αυτών στη θεραπεία της κυστικής ίνωσης, μεθόδους για την παραγωγή τους, φαρμακευτικές συνθέσεις που περιλαμβάνουν αυτές και μεθόδους θεραπείας της κυστικής ίνωσης δια χορήγησης μιας ένωσης της εφεύρεσης.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662345315P | 2016-06-03 | 2016-06-03 | |
PCT/IB2017/053068 WO2017208115A1 (en) | 2016-06-03 | 2017-05-24 | Heteroaryl substituted pyridines and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124031T1 true CY1124031T1 (el) | 2022-03-24 |
Family
ID=59014678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100646T CY1124031T1 (el) | 2016-06-03 | 2020-07-14 | Ετεροαρυλ υποκατεστημενες πυριδινες και μεθοδοι χρησης |
Country Status (34)
Country | Link |
---|---|
US (2) | US10138227B2 (el) |
EP (1) | EP3464282B1 (el) |
JP (3) | JP6968094B2 (el) |
KR (2) | KR20220162806A (el) |
CN (2) | CN109311864B (el) |
AR (2) | AR108672A1 (el) |
AU (3) | AU2017273215B2 (el) |
BR (1) | BR112018074815A2 (el) |
CA (1) | CA3022216A1 (el) |
CL (1) | CL2018003323A1 (el) |
CO (1) | CO2018012171A2 (el) |
CR (1) | CR20180547A (el) |
CY (1) | CY1124031T1 (el) |
DK (1) | DK3464282T3 (el) |
DO (1) | DOP2018000257A (el) |
EC (1) | ECSP18094790A (el) |
ES (1) | ES2806873T3 (el) |
HR (1) | HRP20201068T1 (el) |
HU (1) | HUE050248T2 (el) |
IL (3) | IL288243B2 (el) |
LT (1) | LT3464282T (el) |
MX (2) | MX2018014758A (el) |
PE (1) | PE20190511A1 (el) |
PH (1) | PH12018502534B1 (el) |
PL (1) | PL3464282T3 (el) |
PT (1) | PT3464282T (el) |
RS (1) | RS60574B1 (el) |
RU (2) | RU2021127810A (el) |
SG (1) | SG11201808842VA (el) |
SI (1) | SI3464282T1 (el) |
TW (3) | TWI752961B (el) |
UY (1) | UY37272A (el) |
WO (1) | WO2017208115A1 (el) |
ZA (1) | ZA201808423B (el) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100921397B1 (ko) * | 2009-02-09 | 2009-10-14 | (주)오엠티 | 인쇄회로기판의 세척장비 및 이를 이용한 세척방법 |
CN112250627B (zh) | 2014-10-06 | 2024-02-02 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
US10138227B2 (en) * | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
EP3519401B1 (en) | 2016-09-30 | 2021-09-29 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
IL277491B (en) | 2016-12-09 | 2022-08-01 | Vertex Pharma | Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator |
EP3558982A1 (en) | 2016-12-20 | 2019-10-30 | AbbVie S.À.R.L. | Deuterated cftr modulators and methods of use |
TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
EP3634402A1 (en) | 2017-06-08 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
CN111051280B (zh) | 2017-08-02 | 2023-12-22 | 弗特克斯药品有限公司 | 制备吡咯烷化合物的方法 |
US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
MX2020005753A (es) | 2017-12-08 | 2020-08-20 | Vertex Pharma | Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica. |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
MD3752510T2 (ro) | 2018-02-15 | 2023-06-30 | Vertex Pharma | Macrociclii ca modulatori ai regulatorului conductanței transmembranare în fibroza chistică, compoziții farmaceutice ale acestora, utilizarea lor în tratamentul fibrozei chistice, și procedeu pentru fabricarea acestora |
US10710994B2 (en) * | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
WO2019193062A1 (en) | 2018-04-03 | 2019-10-10 | Abbvie S.Á.R.L | Substituted pyrrolidines and their use |
EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
IT201900000687A1 (it) * | 2019-01-16 | 2020-07-16 | Fondazione St Italiano Tecnologia | Composti e composizioni per il trattamento della fibrosi cistica |
US11345691B2 (en) | 2019-06-03 | 2022-05-31 | AbbVie Global Enterprises Ltd. | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
TW202115014A (zh) | 2019-07-12 | 2021-04-16 | 美商奧佛麥德公司 | 用於治療囊腫纖維化之化合物 |
BR112022002605A2 (pt) | 2019-08-14 | 2022-05-03 | Vertex Pharma | Formas cristalinas de moduladores de cftr |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
CN115003659A (zh) * | 2019-11-12 | 2022-09-02 | 健赞公司 | 用于治疗由cftr活性缺乏介导的疾患的5元杂芳基氨基磺酰胺 |
AU2021329507A1 (en) | 2020-08-20 | 2023-03-09 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating respiratory diseases characterized by mucus hypersecretion |
US20220211692A1 (en) | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
US20220213041A1 (en) | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
WO2023021020A1 (en) | 2021-08-19 | 2023-02-23 | Syngenta Crop Protection Ag | Method for controlling diamide resistant pests & compounds therefor |
WO2024056798A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
WO2024056791A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0509282A (pt) * | 2004-03-30 | 2007-09-18 | Univ California | compostos contendo hidrazida inibidores de cftr e seus usos |
EP1765347A4 (en) | 2004-06-04 | 2008-10-01 | Univ California | COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE |
ME02970B (me) | 2004-06-24 | 2018-07-20 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
US8283351B2 (en) * | 2007-04-02 | 2012-10-09 | Institute For Oneworld Health | Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof |
HUE025553T2 (en) | 2007-05-25 | 2016-02-29 | Vertex Pharma | CFTR modulators |
CL2008003651A1 (es) | 2007-12-10 | 2009-06-19 | Novartis Ag | Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias. |
EP2231671B1 (en) | 2007-12-13 | 2013-04-24 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
AU2009308284B2 (en) * | 2008-10-23 | 2016-02-04 | Vertex Pharmaceuticals, Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
KR20110074916A (ko) | 2008-10-23 | 2011-07-04 | 버텍스 파마슈티칼스 인코포레이티드 | N-(4-(7-아자비시클로[2.2.1]헵탄-7-일)-2-(트리플루오로메틸)페닐)-4-옥소-5-(트리플루오로메틸)-1,4-디히드로퀴놀린-3-카르복스아미드의 고체 형태 |
EP2382197B1 (en) | 2008-12-30 | 2016-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2011008931A2 (en) * | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
US8247436B2 (en) * | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
BR112013007907A2 (pt) | 2010-10-08 | 2016-06-14 | N30 Pharmaceuticals Inc | novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase |
WO2012154880A1 (en) * | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
ES2716723T3 (es) | 2011-09-20 | 2019-06-14 | Univ North Carolina Chapel Hill | Regulación de los canales de sodio por las proteínas PLUNC |
WO2014180562A1 (en) | 2013-05-07 | 2014-11-13 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis |
SG11201600891UA (en) | 2013-08-08 | 2016-03-30 | Galapagos Nv | Thieno[2,3-c]pyrans as cftr modulators |
CA2942386A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
AU2015229117A1 (en) | 2014-03-13 | 2016-09-29 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
BR112017009194A2 (pt) | 2014-10-31 | 2017-12-26 | Abbvie Sarl | tetra-hidropiranos substituídos e método de uso |
SG11201703391VA (en) | 2014-10-31 | 2017-05-30 | Abbvie S À R L | Substituted chromanes and method of use |
US10196384B2 (en) * | 2015-03-31 | 2019-02-05 | Vertex Pharmaceuticals (Europe) Limited | Deuterated CFTR modulators |
JP2018516932A (ja) | 2015-06-02 | 2018-06-28 | アッヴィ・エス・ア・エール・エル | 置換ピリジンおよび使用方法 |
US9840513B2 (en) | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
BR112018007145A2 (pt) | 2015-10-09 | 2018-11-06 | AbbVie S.à.r.l. | ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso |
PL3359541T3 (pl) | 2015-10-09 | 2021-01-11 | AbbVie Overseas S.à r.l. | N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA |
EP3448842A1 (en) | 2016-04-26 | 2019-03-06 | AbbVie S.À.R.L. | Modulators of cystic fibrosis transmembrane conductance regulator protein |
US10138227B2 (en) * | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
-
2017
- 2017-05-23 US US15/602,892 patent/US10138227B2/en active Active
- 2017-05-24 RU RU2021127810A patent/RU2021127810A/ru unknown
- 2017-05-24 JP JP2018552704A patent/JP6968094B2/ja active Active
- 2017-05-24 CN CN201780033214.0A patent/CN109311864B/zh active Active
- 2017-05-24 KR KR1020227040379A patent/KR20220162806A/ko not_active Application Discontinuation
- 2017-05-24 CN CN202210433324.9A patent/CN114671864A/zh active Pending
- 2017-05-24 RU RU2018138707A patent/RU2756743C2/ru active
- 2017-05-24 SI SI201730320T patent/SI3464282T1/sl unknown
- 2017-05-24 WO PCT/IB2017/053068 patent/WO2017208115A1/en unknown
- 2017-05-24 IL IL288243A patent/IL288243B2/en unknown
- 2017-05-24 SG SG11201808842VA patent/SG11201808842VA/en unknown
- 2017-05-24 PL PL17728272T patent/PL3464282T3/pl unknown
- 2017-05-24 CA CA3022216A patent/CA3022216A1/en active Pending
- 2017-05-24 HU HUE17728272A patent/HUE050248T2/hu unknown
- 2017-05-24 DK DK17728272.0T patent/DK3464282T3/da active
- 2017-05-24 PE PE2018003091A patent/PE20190511A1/es unknown
- 2017-05-24 CR CR20180547A patent/CR20180547A/es unknown
- 2017-05-24 BR BR112018074815-3A patent/BR112018074815A2/pt active Search and Examination
- 2017-05-24 AU AU2017273215A patent/AU2017273215B2/en active Active
- 2017-05-24 ES ES17728272T patent/ES2806873T3/es active Active
- 2017-05-24 PT PT177282720T patent/PT3464282T/pt unknown
- 2017-05-24 LT LTEP17728272.0T patent/LT3464282T/lt unknown
- 2017-05-24 IL IL303196A patent/IL303196A/en unknown
- 2017-05-24 KR KR1020187031861A patent/KR102469995B1/ko active IP Right Grant
- 2017-05-24 RS RS20200829A patent/RS60574B1/sr unknown
- 2017-05-24 EP EP17728272.0A patent/EP3464282B1/en active Active
- 2017-05-24 MX MX2018014758A patent/MX2018014758A/es unknown
- 2017-06-02 AR ARP170101516A patent/AR108672A1/es active IP Right Grant
- 2017-06-02 UY UY0001037272A patent/UY37272A/es unknown
- 2017-06-03 TW TW106118418A patent/TWI752961B/zh active
- 2017-06-03 TW TW112108367A patent/TW202329959A/zh unknown
- 2017-06-03 TW TW110149319A patent/TWI797926B/zh active
-
2018
- 2018-10-16 IL IL262415A patent/IL262415B/en unknown
- 2018-10-19 US US16/165,662 patent/US10604515B2/en active Active
- 2018-11-13 CO CONC2018/0012171A patent/CO2018012171A2/es unknown
- 2018-11-22 CL CL2018003323A patent/CL2018003323A1/es unknown
- 2018-11-26 DO DO2018000257A patent/DOP2018000257A/es unknown
- 2018-11-29 PH PH12018502534A patent/PH12018502534B1/en unknown
- 2018-11-29 MX MX2021009322A patent/MX2021009322A/es unknown
- 2018-12-13 ZA ZA2018/08423A patent/ZA201808423B/en unknown
- 2018-12-26 EC ECSENADI201894790A patent/ECSP18094790A/es unknown
-
2020
- 2020-07-07 HR HRP20201068TT patent/HRP20201068T1/hr unknown
- 2020-07-14 CY CY20201100646T patent/CY1124031T1/el unknown
-
2021
- 2021-10-25 JP JP2021173679A patent/JP7392211B2/ja active Active
- 2021-12-07 AU AU2021282409A patent/AU2021282409B2/en active Active
-
2022
- 2022-02-18 AR ARP220100344A patent/AR124916A2/es unknown
-
2023
- 2023-03-27 JP JP2023049450A patent/JP2023172889A/ja active Pending
-
2024
- 2024-04-16 AU AU2024202468A patent/AU2024202468A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124031T1 (el) | Ετεροαρυλ υποκατεστημενες πυριδινες και μεθοδοι χρησης | |
CY1123761T1 (el) | Τροποποιητες της πρωτεϊνης ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης και μεθοδοι χρησης | |
CY1121027T1 (el) | Θeieno[2,3-c]πypania ως διαμορφωτες cftr | |
CY1122542T1 (el) | Νεα παραγωγα υδροξυεστερα, μια διεργασια για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα | |
CY1122870T1 (el) | Νεα πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που τα περιεχουν | |
CY1121804T1 (el) | Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους | |
CY1123186T1 (el) | Μακροκυκλικοι mcl1 αναστολεις για τη θεραπευτικη αντιμετωπιση του καρκινου | |
CY1124620T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
PH12017502201A1 (en) | Substituted pyridines and method of use | |
CY1121706T1 (el) | Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης | |
CY1124496T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
CY1124239T1 (el) | Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου | |
CY1121901T1 (el) | Ενωσεις τριαζολοπυριμιδινης και χρησεις αυτων | |
CY1122560T1 (el) | Νεα παραγωγα αμμωνιου, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουναυτα | |
CY1123069T1 (el) | Νεα (ετερο)αρυλ-υποκατεστημενα-πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα | |
CY1123645T1 (el) | Δικυκλικα παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα | |
MX2019004019A (es) | Pirrolidinas sustituidas como moduladores cftr. | |
MX2019004018A (es) | Pirrolidinas sustituidas y sus usos en el tratamiento de la fibrosis quistica. | |
CY1123349T1 (el) | Ενωσεις 6-ετεροκυκλυλ-4-μορφολιν-4-υλπυρiδιν-2-οnhς χρησιμες για τη θεραπεια καρκινου και διαβητη | |
CY1118656T1 (el) | Παραγωγο πυριδονης | |
CY1123417T1 (el) | Παραγωγα τετρα�δροϊσοκινολινης | |
CY1121395T1 (el) | Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6 | |
MX2015015412A (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica. | |
CY1123494T1 (el) | Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2 |